Literature DB >> 26801159

Targeting Transcriptional and Epigenetic Reprogramming in Stromal Cells in Fibrosis and Cancer.

Nasun Hah1, Mara H Sherman1, Ruth T Yu1, Michael Downes1, Ronald M Evans2.   

Abstract

The basis of many human diseases arises from both genetic and epigenetic regulation. Recent advances in the understanding of the mechanisms underlying transcriptional and epigenetic regulation and their prevalence as contributors to a diverse range of human diseases have led us to focus on transcription and epigenetic changes in a variety of human disease conditions. Specifically, our recent studies in liver fibrosis and pancreatic cancer have demonstrated that the epigenetic regulation in hepatic stellate cells (HSCs) and pancreatic stellate cells (PSCs) significantly contributes to the progress in such diseases and presents great therapeutic potential. We show that the vitamin D receptor (VDR) acts as a master genomic suppressor in both HSC and PSC activation. The studies also have demonstrated that the VDR ligand reduces fibrosis and inflammation in a murine liver fibrosis and pancreatitis model. Although our current studies focus on characterizing the roles of VDR and regulatory regions within gene promoters and regulatory enhancers, we have expanded our effort to epigenetic mechanisms as major determinants of gene activation and repression in order to develop potential therapeutics to modulate stroma-associated pathologies including inflammation, fibrosis, and cancer.
Copyright © 2015 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26801159     DOI: 10.1101/sqb.2015.80.027185

Source DB:  PubMed          Journal:  Cold Spring Harb Symp Quant Biol        ISSN: 0091-7451


  7 in total

Review 1.  Molecular and cellular mechanisms of liver fibrosis and its regression.

Authors:  Tatiana Kisseleva; David Brenner
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-10-30       Impact factor: 46.802

2.  Identification of a novel therapeutic candidate, NRK, in primary cancer-associated fibroblasts of lung adenocarcinoma microenvironment.

Authors:  Tongtong Wei; Jinjing Song; Kai Liang; Li Li; Xiaoxiang Mo; Zhiguang Huang; Gang Chen; Naiquan Mao; Jie Yang
Journal:  J Cancer Res Clin Oncol       Date:  2021-01-02       Impact factor: 4.553

Review 3.  Reengineering the Tumor Microenvironment to Alleviate Hypoxia and Overcome Cancer Heterogeneity.

Authors:  John D Martin; Dai Fukumura; Dan G Duda; Yves Boucher; Rakesh K Jain
Journal:  Cold Spring Harb Perspect Med       Date:  2016-12-01       Impact factor: 6.915

Review 4.  Activated Fibroblast Program Orchestrates Tumor Initiation and Progression; Molecular Mechanisms and the Associated Therapeutic Strategies.

Authors:  Go J Yoshida; Arata Azuma; Yukiko Miura; Akira Orimo
Journal:  Int J Mol Sci       Date:  2019-05-07       Impact factor: 5.923

Review 5.  BRD4 inhibition for the treatment of pathological organ fibrosis.

Authors:  Matthew S Stratton; Saptarsi M Haldar; Timothy A McKinsey
Journal:  F1000Res       Date:  2017-06-28

Review 6.  Shattering the castle walls: Anti-stromal therapy for pancreatic cancer.

Authors:  Ozkan Kanat; Hulya Ertas
Journal:  World J Gastrointest Oncol       Date:  2018-08-15

7.  Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions.

Authors:  Wei Lin; Pawan Noel; Erkut H Borazanci; Jeeyun Lee; Albert Amini; In Woong Han; Jin Seok Heo; Gayle S Jameson; Cory Fraser; Margaux Steinbach; Yanghee Woo; Yuman Fong; Derek Cridebring; Daniel D Von Hoff; Joon Oh Park; Haiyong Han
Journal:  Genome Med       Date:  2020-09-29       Impact factor: 11.117

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.